文献速递腹部PETMR

PET/MR对肝转移瘤诊断价值的评估

Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases.
PubMed 文献 · Invest Radiol · 2021-01-01

这项多中心回顾性研究纳入79例确诊肝外实体恶性肿瘤患者,比较PET/MR与单独PET、单独MRI对疑似肝转移瘤的检测和定性能力。PET/MR的敏感度95%、特异度97%、阳性预测值97%、阴性预测值95%,均优于单独MRI(88%、98%、98%、90%)和单独PET(83%、97%、97%、86%);PET/MR的AUC为95%,高于MRI和PET的92%。结论认为,增强PET/MR在疑似肝转移瘤场景下较单独PET或MRI具有更高的敏感度和阴性预测值,且被判定为不确定的病灶更少。

要点

  • 疑似肝转移瘤患者中,PET/MR的敏感度(95%)和阴性预测值(95%)高于单独MRI或PET。
  • PET/MR判定为不确定的病灶数量少于单独PET和单独MRI。
  • PET/MR的AUC为95%,略高于单独MRI和PET的92%。

核心结论

  • 增强PET/MR在疑似肝转移瘤诊断中较单独PET或单独MRI具有更高的敏感度和阴性预测值。
  • PET/MR较单独PET和单独MRI能减少被定性为不确定的病灶数量。
  • PET/MR的优越性能可能影响疑似肝转移瘤患者的治疗和管理决策。

研究设计与样本

  • 多机构回顾性性能研究,经机构审查委员会批准并符合HIPAA,豁免知情同意。
  • 纳入79例确诊肝外实体恶性肿瘤患者,于2017年2月至2018年6月期间接受上腹部PET/MR检查。
  • 由3名阅片者(1名核医学医师和2名放射科医师)对MRI、PET和PET/MRI分别按有序量表评定肝局灶性病变为肝转移瘤的可能性。
  • 记录每例患者病灶数量、病灶大小及受累肝段;转移瘤证据基于组织病理学或临床/影像随访。
  • 诊断性能采用敏感度、特异度、阳性预测值、阴性预测值和受试者工作特征曲线分析评估。

诊断标准与关键数值

  • PET/MR诊断肝转移瘤的敏感度95%、特异度97%、阳性预测值97%、阴性预测值95%。
  • 单独MRI诊断肝转移瘤的敏感度88%、特异度98%、阳性预测值98%、阴性预测值90%。
  • 单独PET诊断肝转移瘤的敏感度83%、特异度97%、阳性预测值97%、阴性预测值86%。
  • PET/MRI、MRI和PET的曲线下面积分别为95%、92%和92%。

临床应用与阅片要点

  • 在疑似肝转移瘤的评估中,可优先考虑增强PET/MR以提高敏感度和阴性预测值,减少不确定病灶。
  • 单独MRI特异度(98%)略高于PET/MR(97%),需结合临床避免过度诊断。
  • 阅片时应综合MRI形态学与PET代谢信息,并按有序量表记录病灶定性可能性。

局限性

  • 本研究为回顾性设计,可能存在选择偏倚。
  • 样本量79例,来自多机构但样本量有限。
  • 参考标准部分基于临床/影像随访而非全部组织病理学证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The aim of this study was to compare the performance of positron emission tomography (PET)/magnetic resonance (MR) versus stand-alone PET and stand-alone magnetic resonance imaging (MRI) in the detection and characterization of suspected liver metastases.

MATERIALS AND METHODS: This multi-institutional retrospective performance study was approved by the institutional review boards and was Health Insurance Portability and Accountability Act compliant, with waiver of informed consent. Seventy-nine patients with confirmed solid extrahepatic malignancies who underwent upper abdominal PET/MR between February 2017 and June 2018 were included. Where focal hepatic lesions were identified, the likelihood of a diagnosis of a liver metastasis was defined on an ordinal scale for MRI, PET, and PET/MRI by 3 readers: 1 nuclear medicine physician and 2 radiologists. The number of lesions per patient, lesion size, and involved hepatic segments were recorded. Proof of metastases was based on histopathologic correlation or clinical/imaging follow-up. Diagnostic performance was assessed using sensitivity, specificity, positive and negative predictive values, and receiver operator characteristic curve analysis.

RESULTS: A total of 79 patients (53 years, interquartile range, 50-68; 43 men) were included. PET/MR had a sensitivity of 95%, specificity of 97%, positive predictive value of 97%, and negative predictive value of 95%. The sensitivity, specificity, positive predictive value, and negative predictive value of MRI were 88%, 98%, 98%, and 90% and for PET were 83%, 97%, 97%, and 86%, respectively. The areas under the curve for PET/MRI, MRI, and PET were 95%, 92%, and 92%, respectively.

CONCLUSIONS: Contrast-enhanced PET/MR has a higher sensitivity and negative predictive value than either PET or MRI alone in the setting of suspected liver metastases. Fewer lesions were characterized as indeterminate by PET/MR in comparison with PET and MRI. This superior performance could potentially impact treatment and management decisions for patients with suspected liver metastases.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang C, O'Shea A, Parente CA, et al. Evaluation of the Diagnostic Performance of Positron Emission Tomography/Magnetic Resonance for the Diagnosis of Liver Metastases. Invest Radiol. 2021. PMID: 33813576. doi:10.1097/RLI.0000000000000782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。